Bullish Case: Pfizer's high-quality dividend growth coupled with potential international adoption of its products in the Dermatophytosis drugs, Neurodegenerative disease drugs, gastrointestinal drugs, and Rickets treatment could drive profitable growth[argylereport.com, , argylereport.com, argylereport.com].


Show historical bullish cases

Bearish Case: Pfizer's weakened demand leading to a revised 2023 revenue forecast and closure of its facility in Peapack, NJ indicates business and sectoral challenges that could impact stock price negatively [fox5ny.com].


Show historical bearish cases

Takeaway: Pfizer's outlook is mixed with growth opportunities from new drug products but weighed down by dwindling demand, facility closures, and legal battles. Future events including the outcome of legal battles and market penetration of Pfizer's new drugs will significantly influence stock performance [Endpoints, fox5ny.com, argylereport.com, argylereport.com, argylereport.com, ].


Show historical takeaways

Potential Outcomes:

1. Increase in demand for Pfizer products: if Pfizer's drug products gain traction and achieve market penetration, it could see a significant increase in sales. Probability: 55% [argylereport.com, , argylereport.com, argylereport.com].

2. Cost-cutting measures impact growth: Closure of facilities might reduce overheads and improve profitability. However, job losses and potential morale issues could impact productivity. Probability: 30% [fox5ny.com].

3. Continued adjusted revenue forecast: Pfizer's adjusted revenue forecast could signal challenges in the pharmaceutical industry that could further impact Pfizer's performance. Probability: 50% [fox5ny.com].

4. Legal battles leading to bottlenecks: Continued battles over drug exclusivity could slow down Pfizer's entry into new markets or extensions of patent licenses, potentially limiting revenue growth. Probability: 25% [Endpoints].


November 14, 2023


Pfizer Forecast

[PFE]  Pfizer
Price Forecast: NEUTRAL    Price Action: MEAN REVERTING (?)



Make More Profitable Trades with PFE Forecasts + Trading Strategies







PFE Balanced News:


















Correlated Stock Forecasts

Assets that tend to move strongly with PFE



MRNA Forecast + Options Trading Strategies   [MRNA]  Moderna (0.97)


ATNM Forecast + Options Trading Strategies   [ATNM]  Actinium Pharmaceuticals (0.95)


ES Forecast + Options Trading Strategies   [ES]  Eversource Energy (0.95)


EWH Forecast + Options Trading Strategies   [EWH]  BlackRock Institutional Trust Company N.A. - iShares MSCI Hong Kong (0.94)


AA Forecast + Options Trading Strategies   [AA]  Alcoa (0.93)



Uncorrelated Stock Forecasts

Assets with little price relationship to PFE



SF Forecast + Options Trading Strategies   [SF]  Stifel Financial (0.0)


CB Forecast + Options Trading Strategies   [CB]  Chubb (-0.01)


UGL Forecast + Options Trading Strategies   [UGL]  ProShares Ultra Gold (-0.01)


JDST Forecast + Options Trading Strategies   [JDST]  Direxion Daily Junior Gold Miners Index Be (-0.01)


GPS Forecast + Options Trading Strategies   [GPS]  Gap (0.01)



Anticorrelated Stock Forecasts

Assets that tend to move strongly against PFE



DKNG Forecast + Options Trading Strategies   [DKNG]  DraftKings (-0.92)


SNPS Forecast + Options Trading Strategies   [SNPS]  Synopsys (-0.92)


CBAY Forecast + Options Trading Strategies   [CBAY]  Cymabay Therapeutics (-0.93)


DXJ Forecast + Options Trading Strategies   [DXJ]  WisdomTree Japan Hedged Equity (-0.94)


FTAI Forecast + Options Trading Strategies   [FTAI]  Fortress Transportation and Infrastructure Investors (-0.94)